Skip to content
DataLookout
Menu

ELAPSENCT05976685

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Nov 7, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 21 versions: 21 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 32 → 35 locations
  2. Minor Study sites: 33 to 34
  3. Notable Eligibility criteria expanded, about 24 words
    • Study sites: 32 to 33
    • Secondary endpoints: details revised at 4 of 12 entries
  4. Minor Study sites: 31 to 32v19
  5. Minor Study sites: 30 to 31v18
Show 16 earlier versionsHide 16 earlier versions
  1. Minor Study sites: 29 to 30v17
  2. Minor Study sites: 28 to 29v16
  3. Minor Study sites: 27 to 28v15
  4. Minor Study sites: 25 to 27v14
  5. Minor Study sites: 23 to 25v13
  6. Minor Study sites: 21 to 23v12
  7. Minor Study sites: 18 to 21v11
  8. Minor Study sites: 17 to 18v10
  9. Minor Study sites: 16 to 17v9
  10. Minor Study sites: 12 to 16v8
  11. Minor Study sites: 9 to 12v7
  12. Minor Study sites: 7 to 9v6
  13. Notable Eligibility criteria shortened, about 21 words
    • Site details revised at 2 of 7 sites
    v5
  14. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 7
    v4
  15. Notable Start date: Jan 1, 2024 to May 1, 2024
    • Eligibility criteria expanded, about 108 words
    v3
  16. Notable Eligibility criteria shortened, about 76 words
    • Interventions: DOAC (Drug), Left atrial appendage Occlusion and 3 months of Clopidogrel (Procedure) to DOAC (Drug), Left atrial appendage Occlusion (Procedure)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Composite of recurrent ischemic stroke, systemic embolism, or cardiovascular death (whatever comes first).
Timeframe: 6 months

Secondary (12)

Recurrent ischemic stroke
Systemic embolism
Cardiovascular death
Symptomatic intracranial hemorrhage
Major extracranial bleeding (ISTH)
Show 7 moreShow less
Procedure-related death
Serious device- or procedure-related complication
All-cause hospitalization
Cause-specific hospitalization
Global health
Global safety
Functional neurological outcome

Arms and interventions

LAAO and DOAC therapyExperimental

Left atrial appendage occlusion and therapy with direct oral anticoagulants

DOAC therapy onlyOther

Therapy with direct oral anticoagulants alone

Procedures: Left atrial appendage Occlusion

Drugs: DOAC

Sites

35 sites in 6 countries

Germany 9, Switzerland 8, Belgium 6, Spain 6, United Kingdom 5, New Zealand 1